Sharemaestro company-news research for Faron Pharmaceuticals Oy (FARON), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
HEL
Finland
Provisional evidence
Company news sentiment
FARON news sentiment
Faron Pharmaceuticals Oy
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score50Neutral is 50
Early balanced news score
21/100 evidence confidence
100% direct company focus
6 current stories across 6 publishers
Current company news
Early balanced news score
6 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone50/100
→
Reliability-adjusted score50/100
Latest source headline
Faron Pharmaceuticals shareholder increases stake to 20.72% By Investing.com
Investing.com Canada · 05 Aug 2026 11:34 · Source lookup
Freshness, source quality and evidence depth temper uncertain readings toward 50; confidence remains a separate reliability measure.
What supports the score
6 current stories are mapped specifically to FARON.
The read spans 6 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.053.
Evidence confidence is 21/100, below the threshold for a firm classification.
50/100
News scoreEarly balanced news score
21/100
Confidencethin evidence
100%/100
Company news6 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
15 Jul30 Jul13 Aug
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence1
0.053 after freshness weightingSource breadth100
6 independent publishersCompany relevance100
share tied directly to this companyFreshness21
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix26
less reliance on one publisherPrice and news history
News score and weekly price over 26 weeks
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
07 Aug 202650EUR 0.47-1.2%
31 Jul 202650EUR 0.48+0.6%
24 Jul 202650EUR 0.48-2.5%
17 Jul 202650EUR 0.49-0.3%
10 Jul 202650EUR 0.49-3.1%
03 Jul 202650EUR 0.51+5.0%
26 Jun 202650EUR 0.48-3.0%
Provisional evidence
News subjects
What is shaping the score
Market update504 stories · 67%
Deals and strategy501 stories · 17%
Earnings501 stories · 17%
Source mix
Where the evidence comes from
Investing.com Canada501 stories · 17%
Biostock501 stories · 17%
Market source501 stories · 17%
TradingView501 stories · 17%
marketscreener.com501 stories · 17%
Investing.com501 stories · 17%
Recurring subjects
Subjects appearing most often
Topic structure will appear when classified tags are present in the current feed.
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
20 Jun50 neutral13 Aug 17:00
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 13 Aug 17:00 | 50 | +0 | 21/100 (-7) | 6 (-1) | Provisional |
| 05 Aug 23:59 | 50 | +0 | 28/100 (+5) | 7 (0) | Provisional |
| 31 Jul 23:59 | 50 | +0 | 23/100 (-5) | 7 (0) | Provisional |
| 27 Jul 23:59 | 50 | +0 | 28/100 (+4) | 7 (0) | Provisional |
| 24 Jul 23:59 | 50 | +0 | 24/100 (-2) | 7 (0) | Provisional |
| 16 Jul 23:59 | 50 | +1 | 26/100 (0) | 7 (+1) | Provisional |
| 11 Jul 23:59 | 49 | -1 | 26/100 (+1) | 6 (+1) | Provisional |
| 06 Jul 23:59 | 50 | +0 | 25/100 (0) | 5 (+1) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#150Tone
Investing.com CanadaDirect company coverageScored from headlineSource lookup
Faron Pharmaceuticals shareholder increases stake to 20.72% By Investing.com
- Published
- 05 Aug 2026 11:34
- News subject
- Deals and strategy
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- High · 84.9% · 8.2d old
- Duplicates
- 2 consolidated
#250Tone
BiostockDirect company coverageScored from headlineSource lookup
Faron reports first survival data from the BEXMAB trial
- Published
- 31 Jul 2026 01:52
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.9% · 13.6d old
- Duplicates
- 1 consolidated
#350Tone
Market sourceDirect company coverageScored from headlineSource lookup
Faron Pharmaceuticals shares strengthen on upbeat new cancer trial data
- Published
- 27 Jul 2026 21:54
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.3% · 16.8d old
- Duplicates
- 1 consolidated
#450Tone
TradingViewDirect company coverageScored from headlineSource lookup
Faron Pharmaceuticals Oy Revenue Breakdown – LSE:FARN
- Published
- 27 Jul 2026 05:43
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 13.8% · 17.5d old
- Duplicates
- 1 consolidated
#550Tone
marketscreener.comDirect company coverageScored from headlineSource lookup
Faron Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab
- Published
- 24 Jul 2026 04:47
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 20.5d old
- Duplicates
- 1 consolidated
#650Tone
Investing.comDirect company coverageScored from headlineSource lookup
Faron Pharmaceuticals grants 2.17 million stock options
- Published
- 16 Jul 2026 16:39
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 28.0d old
- Duplicates
- 1 consolidated
Earlier company news
FARON news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above. Where an early legacy import did not retain its canonical URL, the headline links to an exact publisher-aware source lookup instead of inventing an article address.
Jul
11
2026
Motley FoolArchivedLegacy headline · tone unscoredLegacy source lookup
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
- Published
- 11 Jul 2026 22:32
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
06
2026
CNW GroupArchivedLegacy headline · tone unscoredLegacy source lookup
Cipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris®
- Published
- 6 Jul 2026 22:50
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
01
2026
TradingViewArchivedLegacy headline · tone unscoredLegacy source lookup
Price to earnings forward of Faron Pharmaceuticals Oy – LSE:FARN
- Published
- 1 Jul 2026 05:38
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
27
2026
TradingViewArchivedLegacy headline · tone unscoredLegacy source lookup
Faron Pharmaceuticals Oy Actuals & Estimates (LSE:FARN)
- Published
- 27 Jun 2026 01:50
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
26
2026
Investing.comArchivedLegacy headline · tone unscoredLegacy source lookup
Faron Pharmaceuticals receives major holdings notification
- Published
- 26 Jun 2026 09:35
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
25
2026
Investing.com CanadaArchivedLegacy headline · tone unscoredLegacy source lookup
Faron Pharmaceuticals receives major holdings notification By Investing.com
- Published
- 25 Jun 2026 20:28
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
20
2026
Investing.com UKArchivedLegacy headline · tone unscoredLegacy source lookup
Faron Pharmaceuticals shareholder stake falls below 7%
- Published
- 20 Jun 2026 21:34
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.